Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib as the Maintenance Therapy for Extensive-stage Small Cell Lung Cancer After Combined With Etoposide and Cisplatin Chemotherapy

NCT03781869 is registered in ClinicalTrials.gov with Third Military Medical University as lead sponsor.

NCT NCT03781869
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03781869 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib as the Maintenance Therapy for Extensive-stage Small Cell Lung Cancer After Combined With Etoposide and Cisplatin Chemotherapy
Lead sponsor
Third Military Medical University
Phase
Phase 2
Overall status
Unknown status
Start date
December 31, 2018
Completion date
December 31, 2021
Enrollment
116 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

extensive-stage small cell lung cancer